SIOPEN neuroblastoma clinical trials in Australia and New Zealand

This project will facilitate Australian and New Zealand participation in international neuroblastoma clinical trials coordinated by the SIOP-Europe-Neuroblastoma (SIOPEN) trials cooperative group. Neuroblastoma continues to cause a disproportionate number of children’s cancer deaths. The SIOPEN high risk neuroblastoma-2 trial focuses on improving the survival for patients with the lowest chance of cure. The SIOPEN LINES trial is for children with less aggressive tumours. LINES incorporates refined tumour analysis and staging techniques to more easily identify biologically favourable and unfavourable tumours. Patients with biologically favourable tumours will receive less intensive treatments whilst those with unfavourable tumours will receive more intensive treatments